Detailed Notes on E-64
123). It truly is noteworthy that GLS2 is tumorigenic in breast cancer124, and its expression could compensate for loss of Gls in MYC-induced mouse liver tumours40. This suggests that GLS2 could confer resistance to GLS1-distinct inhibitors, such as the allosteric inhibitor BPTES or CB-839, and this resistance can be hypothetically avoided by the u